Pharvaris (NASDAQ:PHVS) Stock Price Expected to Rise, Bank of America Analyst Says

Pharvaris (NASDAQ:PHVS) had its price target upped by research analysts at Bank of America from $27.00 to $30.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Bank of America‘s price target suggests a potential upside of 13.55% from the stock’s current price.

A number of other research firms also recently weighed in on PHVS. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Morgan Stanley boosted their target price on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday. JMP Securities cut their target price on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Zacks Research raised shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $40.56.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $26.42 on Thursday. Pharvaris has a 1 year low of $11.51 and a 1 year high of $29.80. The firm has a market cap of $1.38 billion, a PE ratio of -8.23 and a beta of -2.80. The company has a 50 day simple moving average of $23.81 and a two-hundred day simple moving average of $21.58.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, research analysts anticipate that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its position in shares of Pharvaris by 55.1% in the first quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock valued at $442,000 after acquiring an additional 10,006 shares during the period. Palumbo Wealth Management LLC grew its stake in shares of Pharvaris by 3.2% in the second quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock worth $256,000 after purchasing an additional 447 shares during the last quarter. TD Asset Management Inc increased its holdings in Pharvaris by 27.4% during the 2nd quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after purchasing an additional 21,388 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Pharvaris during the 2nd quarter valued at approximately $57,000. Finally, Geode Capital Management LLC lifted its holdings in Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after buying an additional 15,769 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.